NCT06126419 Application of High-dose Insulin Therapy to Improve Liver Function and Regeneration
| NCT ID | NCT06126419 |
| Status | Recruiting |
| Phase | — |
| Sponsor | McGill University Health Centre/Research Institute of the McGill University Health Centre |
| Condition | Liver Dysfunction |
| Study Type | INTERVENTIONAL |
| Enrollment | 70 participants |
| Start Date | 2023-11-08 |
| Primary Completion | 2026-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 70 participants in total. It began in 2023-11-08 with a primary completion date of 2026-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary objective of this interventional study is determine if the future liver remnant can be optimized by improving liver function pre-operatively in patients who are scheduled for major hepatectomy. The main questions it aims to answer are: 1. Does high-dose insulin therapy improve liver function in the pre-operative setting? 2. What is the effect of high-dose insulin therapy on liver function and liver regeneration after a liver venous deprivation (LVD) procedure? 3. What is the relationship between volume hypertrophy and function in the regenerating liver? Participants will receive a 6-hour infusion of insulin and dextrose to maintain a hyperinsulinemic-normoglycemic state in the weeks prior to planned liver surgery to assess its effect on liver function measured by 99m-Tc-Mebrofenin hepatobiliary scintigraphy.
Eligibility Criteria
Inclusion Criteria: * Age \> 18 years old * Candidate for major liver resection * Resectable colorectal liver metastasis Exclusion Criteria: * Inability to give consent * Type 1 diabetes mellitus * Uncontrolled blood glucose levels (fasting level \> 10 mmol/L) * Unresectable colorectal liver metastasis * Extrahepatic metastatic disease that is unresectable
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06126419 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Liver Dysfunction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06126419 currently recruiting?
Yes, NCT06126419 is actively recruiting participants. Contact the research team at jennifer.kalil@mail.mcgill.ca for enrollment information.
Where is the NCT06126419 trial being conducted?
This trial is being conducted at Montreal, Canada.
Who is sponsoring the NCT06126419 clinical trial?
NCT06126419 is sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. The trial plans to enroll 70 participants.